ZOMETA® – Patient Case Study & Medical Profile of a Lung Cancer Patient - Statistics

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Lung Cancer Patient Case Study – Anthony

Anthony P.

Aged 64 years
Retired auto mechanic
Quit smoking 10 years ago

Page

1 2

Anthony is not alone

30% to 40% of patients with advanced lung cancer will develop bone metastases¹
46% of patients with lung cancer and bone metastases will experience a skeletal-related event (SRE) without treatment²
SREs are generally defined as pathologic fractures, spinal cord compression, radiation or surgery to bone, or tumour-induced hypercalcemia³

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.